Skip to main content
  • Experimental Antiplatelet Drug CG-0255 Shows Advantages over Clopidogrel – Phase I Trial

    PHILADELPHIA – The experimental antiplatelet drug compound CG-0255 demonstrated several advantages over clopidogrel and was well-tolerated by patients, according to new phase I trial results.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details